Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats

Zhou,Xian-Mei; Cao,Zhen-Dong; Xiao,Na; Shen,Qi; Li,Jian-Xin

doi:10.3892/ijmm.2015.2435

Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats

Authors:
- Xian-Mei Zhou
- Zhen-Dong Cao
- Na Xiao
- Qi Shen
- Jian-Xin Li
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of Respiratory Medicine, The Second Affiliated Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210017, P.R. China, State Key Laboratory of Analytical Chemistry for Life Science and Collaborative Innovation Center of Chemistry for Life Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, Jiangsu 210023, P.R. China
Published online on: December 15, 2015 https://doi.org/10.3892/ijmm.2015.2435
Pages: 339-346
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease for which, thus far, there are no effective treatments. The pericarp of Citrus reticulata, as a traditional herbal drug, has been used for the clinical treatment of lung-related diseases in China for many years. In the present study, the amines from the pericarp of Citrus reticulata were isolated, and their hydrochlorides were prepared. The results of screening using cultured human embryonic lung fibroblasts (hELFs) revealed that, of the amines, 4-methoxyphenethylamine hydrochloride (designated as amine hydrochloride 1) possessed the most potent inhibitory effect. Further in vivo experiments using a rat model of bleomycin-induced pulmonary fibrosis demonstrated that the oral administration of amine hydrochloride 1 significantly lowered the hydroxyproline content in both serum and lung tissue, and alleviated pulmonary alveolitis and fibrosis. Immunohistochemical analysis revealed that amine hydrochloride 1 exerted its inhibitory effect against IPF through the downregulation of lung transforming growth factor (TGF)-β1 protein expression. Our results demonstrated that amine hydrochloride 1 prevented the development of bleomycin‑induced lung fibrosis in rats. Thus, our data suggest that the amines from the pericarp of Citrus reticulata have therapeutic potential for use in the treatment of IPF.

View Figures

View References

1	Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
2	Nalysnyk L, Cid-Ruzafa J, Rotella P and Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 21:355–361. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hilberg O, Simonsen U, du Bois R and Bendstrup E: Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J. 6:131–143. 2012. View Article : Google Scholar : PubMed/NCBI
4	O'Connell OJ, Kennedy MP and Henry MT: Idiopathic pulmonary fibrosis: treatment update. Adv Ther. 28:986–999. 2011. View Article : Google Scholar : PubMed/NCBI
5	Armanios M: Telomerase and idiopathic pulmonary fibrosis. Mutat Res. 730:52–58. 2012. View Article : Google Scholar :
6	Rafii R, Juarez MM, Albertson TE and Chan AL: A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 5:48–73. 2013.PubMed/NCBI
7	Spagnolo P, Maher TM and Richeldi L: Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 152:18–27. 2015. View Article : Google Scholar : PubMed/NCBI
8	Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al INPULSIS Trial Investigators: efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
9	King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 370:2083–2092. 2014. View Article : Google Scholar : PubMed/NCBI
10	Cottin V: Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev. 23:225–230. 2014. View Article : Google Scholar : PubMed/NCBI
11	Velasco R and Licciardello C: A genealogy of the citrus family. Nat Biotechnol. 32:640–642. 2014. View Article : Google Scholar : PubMed/NCBI
12	Medina S, Ferreres F, García-Viguera C, Horcajada MN, Orduna J, Savirón M, Zurek G, Martínez-Sanz JM, Gil JI and Gil-Izquierdo A: Non-targeted metabolomic approach reveals urinary metabolites linked to steroid biosynthesis pathway after ingestion of citrus juice. Food Chem. 136:938–946. 2013. View Article : Google Scholar
13	Nile SH and Park SW: Bioactive components and health-promoting properties of Yuzu (Citrus ichangensis x C. reticulate). Food Rev Int. 30:155–167. 2014. View Article : Google Scholar
14	Yadav L and Kalidhar SB: Chemical components of Mandarin species: a review. J Indian Chem Soc. 88:911–926. 2011.
15	Khan MK, Huma ZE and Dangles O: A comprehensive review on flavanones, the major citrus polyphenols. J Food Compos Anal. 33:85–104. 2014. View Article : Google Scholar
16	Vieira SM, Theodoro KH and Glória MBA: Profile and levels of bioactive amines in orange juice and orange soft drink. Food Chem. 100:895–903. 2007. View Article : Google Scholar
17	Stohs SJ, Preuss HG and Shara M: The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine. Phytother Res. 25:1421–1428. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kaats GR, Miller H, Preuss HG and Stohs SJ: A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 55:358–362. 2013. View Article : Google Scholar : PubMed/NCBI
19	Stohs SJ and Preuss HG: Stereochemical and pharmacological differences between naturally occurring p-synephrine and synthetic p-synephrine. J Funct Foods. 4:2–5. 2012. View Article : Google Scholar
20	Zhou XM, Zhang GC, Li JX and Hou J: Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol. 111:255–264. 2007. View Article : Google Scholar
21	Zhou XM, Huang MM, He CC and Li JX: Inhibitory effects of citrus extracts on the experimental pulmonary fibrosis. J Ethnopharmacol. 126:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
22	China Pharmacopoeia Committee: Citri Reticulatae Pericarpium. Chinese Pharmacopeia 2010. Chemical Industry; Press, Beijing: pp. 176–177. 2010
23	Zhou XM, Wen GY, Zhao Y, Liu YM and Li JX: Inhibitory effects of alkaline extract of Citrus reticulata on pulmonary fibrosis. J Ethnopharmacol. 146:372–378. 2013. View Article : Google Scholar : PubMed/NCBI
24	Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 120:893–899. 1979.PubMed/NCBI
25	Camelo A, Dunmore R, Sleeman MA and Clarke DL: The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol. 4:1732014. View Article : Google Scholar : PubMed/NCBI
26	Kendall RT and Feghali-Bostwick CA: Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 5:1232014. View Article : Google Scholar : PubMed/NCBI
27	B Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K and Hogaboam CM: Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 49:167–179. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kliment CR, Englert JM, Crum LP and Oury TD: A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal. Int J Clin Exp Pathol. 4:349–355. 2011.PubMed/NCBI
29	Huaux F, Noel S, Dhooghe B, Panin N, Lo Re S, Lison D, Wallemacq P, Marbaix E, Scholte BJ, Lebecque P and Leal T: Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One. 8:e643412013. View Article : Google Scholar : PubMed/NCBI
30	Yan Z, Kui Z and Ping Z: Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev. 13:1020–1025. 2014. View Article : Google Scholar : PubMed/NCBI
31	Klingberg F, Hinz B and White ES: The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 229:298–309. 2013. View Article : Google Scholar
32	Della Latta V, Cecchettini A, Del Ry S and Morales MA: Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res. 97:122–130. 2015. View Article : Google Scholar : PubMed/NCBI